Evolent Health price target lowered to $45 from $47 at Canaccord
The Fly

Evolent Health price target lowered to $45 from $47 at Canaccord

Canaccord lowered the firm’s price target on Evolent Health to $45 from $47 and keeps a Buy rating on the shares. The firm said they remain encouraged with Evolent’s performance and believe the company sits in a unique position to assist managed care in addressing rising medical costs trends with specialty care management offerings targeting cardiovascular, musculoskeletal, and oncology care.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See today’s best-performing stocks on TipRanks >>

Read More on EVH:

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App